Exicure, Inc.

150 articles about Exicure, Inc.

• Exicure Presents Positive Clinical Data with Cavrotolimod at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

  11/9/2020

  Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing proprietary spherical nucleic acid (SNA™) technology, today announced the presentation of updated Phase 1b data from the ongoing Phase 1b/2 clinical trial evaluating intratumoral cavrotolimod

• Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

  10/19/2020

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing proprietary spherical nucleic acid technology, announced an upcoming poster presentation for its intratumoral product candidate, cavrotolimod, at the 35th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer, to be held virtually from November 9-14, 2020.

• Exicure to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference

  10/5/2020

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced a presentation at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020.

• Exicure Secures Debt Facility for Up to $25.0 Million

  10/1/2020

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced it has entered into a $25.0 million senior secured term loan with MidCap Financial Trust, as agent, and Silicon Valley Bank.

• 

  Clinical Catch-Up: September 14-18

  9/21/2020

  It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
• 

  Exicure Announces Positive Phase Ib Trial Results for Solid Tumor Treatment Cavrotolimod

  9/17/2020

  Exicure announced positive results from its Phase Ib trial evaluating cavrotolimod, its SNA-enabled TLR9 agonist, that is being developed for the treatment of solid tumors, in combination with pembrolizumab.

• Exicure Presents Promising Interim Results from Ongoing Phase 1b/2 Trial of Cavrotolimod at Virtual KOL Event Today

  9/16/2020

  Confirmed overall response rate (ORR) of 21% in the dose-escalation stage across all doses, confirmed ORR 33% at the highest and selected Phase 2 dose Target tumor shrinkage was observed in 37% of patients Preliminary data show activity in patients with melanoma, Merkel cell carcinoma (MCC), and cutaneous squamous cell carcinoma (CSCC) Phase 2 arms in both MCC and CSCC are currently recruiting CHICAGO & CAMBRIDGE,

• Exicure to Present at Upcoming Conferences

  9/10/2020

  Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced presentations at the following conferences during the month of September: TIDES: Oligonucleotide & Peptide Therapeutics Panel discussion: The impact of technological advances in the TIDES Space Presented by: CEO David Giljohann Tue

• Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy Data for Cavrotolimod

  8/25/2020

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, announced that it will host a virtual KOL meeting on Wednesday, September 16th, 2020 from 10:30 am-12 pm ET to discuss the preliminary Phase 1b efficacy and safety data for cavrotolimod, Exicure’s SNA-enabled TLR9 agonist for solid tumors.

• Exicure, Inc. Reports Second Quarter 2020 Financial Results and Corporate Progress

  8/12/2020

  Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter and six months ended June 30, 2020 and provided an update on corporate progress.

• Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference 2020

  8/5/2020

  Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that David Giljohann, CEO, will present a Fireside Chat at the BTIG Virtual Biotechnology Conference 2020 on Monday, August 10, 2020. Date: Monday, August 10, 2020 Time: 1:30 PM Eastern Time Location: Virtual Webcast The presentation wi

• Exicure, Inc. Added to Russell 2000® Index

  6/29/2020

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, announced that it has been added to the Russell 2000® index.

• Exicure Presents Cavrotolimod (AST-008) Clinical Data at AACR 2020 Virtual Meeting

  6/22/2020

  Poster presentation of pharmacodynamic and safety data of cavrotolimod (AST-008) from Exicure’s ongoing Phase 1b/2 clinical trial in solid tumor patients

• Exicure, Inc. to Present at the 2020 BMO Prescription for Success Healthcare Conference

  6/18/2020

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that Dr. David Giljohann, Chief Executive Officer of Exicure, will present a corporate update at the virtual 2020 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 4:30 p.m. EDT.

• Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008)

  6/16/2020

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced the dosing of the first patient enrolled in the Phase 2 dose expansion stage of the cavrotolimod Phase 1b/2 clinical trial.

• Exicure, Inc. to Present at Jefferies 2020 Healthcare Conference

  5/20/2020

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the virtual Jefferies 2020 Healthcare Conference on Thursday, June 4, 2020 at 1:00 p.m. EDT.

• Exicure Announces Appointment of Dr. Douglas E. Feltner as Chief Medical Officer

  5/19/2020

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that it has appointed Douglas E. Feltner, M.D. as its Chief Medical Officer effective May 18th, 2020.

• Exicure to Present Clinical Data at AACR 2020 Virtual Meeting

  5/15/2020

  Poster presentation will show updated pharmacodynamic and safety data of AST-008 from Exicure’s ongoing Phase 1b/2 study

• Exicure, Inc. Reports First Quarter 2020 Financial Results and Corporate Progress

  5/14/2020

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, reported financial results for the quarter ended March 31, 2020 and provided an update on corporate progress.

• Exicure to Present at the American Society of Clinical Oncology 2020

  5/14/2020

  Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, will present a poster at the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place virtually from May 29-31. The ASCO poster, by Dr. Mohammed Milhem of the University of Iowa and coauthors, titled “AST-008: A Novel Approach to TLR